Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228
The purpose of this study is to evaluate the safety and tolerability of extended treatment with FK228 in patients with metastatic renal cell carcinoma or hormone refractory prostate cancer who have at least demonstrated stable disease on prior Fujisawa sponsored FK228 clinical trials.
Carcinoma, Renal Cell|Prostatic Neoplasms
DRUG: FK228 (romidepsin)
Number of participants with adverse events, Up to 6 months
To evaluate the effect of depsipeptide therapy on performance status as measured by the Karnofsky score assessment, Up to 6 months|To evaluate the time to objective disease progression., Up to 6 months
This is a Phase II, non-randomized, open-label, single arm, continuation trial.